Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH) trial: study protocol for a multicentre, randomised controlled trial
Melanie Meersch, Mira Küllmar, Carola Wempe, Detlef Kindgen-Milles, Stefan Kluge, Torsten Slowinski, Gernot Marx, Joachim Gerss, Alexander Zarbock, SepNet Critical Care Trials Group, Melanie Meersch, Mira Küllmar, Carola Wempe, Detlef Kindgen-Milles, Stefan Kluge, Torsten Slowinski, Gernot Marx, Joachim Gerss, Alexander Zarbock, SepNet Critical Care Trials Group
Abstract
Introduction: Acute kidney injury (AKI) is a well-recognised complication of critical illness which is of crucial importance for morbidity, mortality and health resource utilisation. Renal replacement therapy (RRT) inevitably entails an escalation of treatment complexity and increases costs for those patients with severe AKI. However, it is still not clear whether regional citrate anticoagulation or systemic heparin anticoagulation for continuous RRT (CRRT) is most appropriate. We hypothesise that, in contrast to systemic heparin anticoagulation, regional citrate anticoagulation for CRRT prolongs filter life span and improves overall survival in a 90-day follow-up period (coprimary endpoints).
Methods and analysis: We will conduct a prospective, randomised, multicentre, clinical trial including up to 1450 critically ill patients with AKI requiring CRRT. We suggest to investigate the effect of regional citrate anticoagulation for CRRT as compared with systemic heparin anticoagulation. The two coprimary outcomes are filter life span and overall survival in a 90-day follow-up period. Secondary outcomes are length of stay in the intensive care unit; length of hospitalisation; duration of CRRT; recovery of renal function at days 28, 60, 90 and 1 year; requirement for RRT after days 28, 60, 90 and 1 year; 28 days, 60 days, 90 days and 1-year all-cause mortality; major adverse kidney events at days 28, 60, 90 and 1 year; bleeding complications; transfusion requirements; infection rate and costs of RRT. Additionally, in an add-on study involving several of the participating centres, blood samples from recruited patients will be collected at different time points to analyse whether the anticoagulation strategy has an impact on immune response as evidenced by leucocyte recruitment and function.
Ethics and dissemination: The RICH trial has been approved by the Federal Institute for Drugs and Medical Devices, the leading Ethics Committee of the University of Münster and the corresponding Ethics Committee at each participating site.
Trial registration number: NCT02669589.
Keywords: acute renal failure; anticoagulation.
Conflict of interest statement
Competing interests: None declared.
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Figures
References
- Hoste EA, Bagshaw SM, Bellomo R, et al. . Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med 2015;41:1411–23. 10.1007/s00134-015-3934-7
- Uchino S, Bellomo R, Morimatsu H, et al. . External validation of severity scoring systems for acute renal failure using a multinational database. Crit Care Med 2005;33:1961–7. 10.1097/01.CCM.0000172279.66229.07
- Metnitz PGH, Krenn CG, Steltzer H, et al. . Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients*. Crit Care Med 2002;30:2051–8. 10.1097/00003246-200209000-00016
- Kellum JA, Angus DC. Patients are dying of acute renal failure *. Crit Care Med 2002;30:2156–7. 10.1097/00003246-200209000-00041
- Gattas DJ, Rajbhandari D, Bradford C, et al. . A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically Ill Adults. Crit Care Med 2015;43:1622–9. 10.1097/CCM.0000000000001004
- Bai M, Zhou M, He L, et al. . Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs. Intensive Care Med 2015;41:2098–110. 10.1007/s00134-015-4099-0
- Hetzel GR, Schmitz M, Wissing H, et al. . Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrol Dial Transplant 2011;26:232–9. 10.1093/ndt/gfq575
- Oudemans-van Straaten HM, Bosman RJ, Koopmans M, et al. . Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009;37:545–52. 10.1097/CCM.0b013e3181953c5e
- Schilder L, Nurmohamed SA, Bosch FH, et al. . Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Crit Care 2014;18:472 10.1186/s13054-014-0472-6
- Wu MY, Hsu YH, Bai CH, et al. . Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2012;59:810–8. 10.1053/j.ajkd.2011.11.030
- Zhang Z, Hongying N. Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy. Intensive Care Med 2012;38:20–8. 10.1007/s00134-011-2438-3
- Singer M, Deutschman CS, Seymour CW, et al. . The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016;315:801–10. 10.1001/jama.2016.0287
- Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103–15. 10.2307/2529712
- Uchino S, Bellomo R, Morimatsu H, et al. . Discontinuation of continuous renal replacement therapy: a post hoc analysis of a prospective multicenter observational study. Crit Care Med 2009;37:2576–82. 10.1097/CCM.0b013e3181a38241
- Bauer P. Multiple testing in clinical trials. Stat Med 1991;10:871–90. 10.1002/sim.4780100609
- Kellum J ALN, Aspelin P, Barsoum RS, et al. . KDIGO clinical practice guideline for acte kidney injury 2012. Kidney Int Suppl 2012;2:1–138.
- Thompson A, Li F, Gross AK. Considerations for medication management and anticoagulation during continuous renal replacement therapy. AACN Adv Crit Care 2017;28:51–63. 10.4037/aacnacc2017386
- Brophy PD, Somers MJ, Baum MA, et al. . Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT). Nephrol Dial Transplant 2005;20:1416–21. 10.1093/ndt/gfh817
Source: PubMed